News Health & Medicine Best choice for chronic leukemia treatment may change Newer drug outperforms Gleevec in trial By Nathan Seppa December 8, 2009 at 7:03 pm - More than 2 years ago Share this:Share Share via email (Opens in new window) Email Click to share on Facebook (Opens in new window) Facebook Click to share on Reddit (Opens in new window) Reddit Click to share on X (Opens in new window) X Click to print (Opens in new window) Print NEW ORLEANS — People fighting chronic myeloid leukemia got a double dose of good news at the meeting of the American Society of Hematology. The drug nilotinib, marketed as Tasigna, proved better than the reigning frontline drug used against CML, a new study finds.